Prospective Two-arm Study of Fertility in Men With COVID-19

I.M. Sechenov First Moscow State Medical University

Status: Unknown

Conditions: Covid19; Fertility Issues

Treatments: Diagnostic Test: hormone levels (testosterone, FSH, LH, prolactin); Other: Testis pathology samples; Diagnostic Test: SARS-CoV-2 Ig G levels; Diagnostic Test: Sperm test

Study type: Interventional

Funder types: Other

Identifiers

NCT04716179

COVID-MFert-20

Details and patient eligibility

About

COVID-19 infection is hypothesized to have a potentially negative effect on male fertility through direct damage to the testes. The current trial is aimed at investigating the effect of SARS-CoV-2 on fertility and determining if viral bodies are capable of directly damaging testicular cells

Full description

In late December 2019, the Chinese city of Wuhan witnessed the emergence of a form of pneumonia of unknown etiology. By the middle of January 2020, the disease had managed to spread beyond the country of origin and is now classified by the WHO as the largest pandemic in modern history.

Rapidly spreading and highly contagious, the infection prompted medical professionals all over the world to begin research into the virus with the goal of developing early diagnostic techniques and treatment strategies.

The new pathogen named SARS-Cov-2 belongs to the Coronaviridae family. These viruses cause severe acute respiratory syndrome (SARS-CoV-1, 2002-2003) and Middle East respiratory syndrome (MERS, 2012-2013).

The effects of SARS-CoV-2 on the human body stem from its structure. The spike proteins on the surface of the virus, which are responsible for the name "Coronaviridae," means that it is able to bind to the host receptor protein, angiotensin-converting enzyme 2 (ACE2). This makes cells with high quantities of these receptors on the surface susceptible to the virus.

The genome of SARS-Cov-2 responsible for the COVID-19 pandemic contains both human coronavirus fragments and bat coronavirus fragments (HKU9-1). It is the genetic material of HKU9-1 that makes SARS-CoV-2 unknown to the immune system of the human body.

As of today, three transmission pathways are recognized: close contact, airborne and fomite. Moreover, the virus is known to retain its contagious properties on surfaces for up to 72 hours, and the incubation period ranges between 2 and 14 days. Recent reports indicate that up to 80% of those infected by COVID-19 showed mild or moderate symptoms whereas 20-30% develop severe forms of the disease characterized by shock as well as respiratory and multiple organ failure. According to Chinese and Italian healthcare providers, the mortality rate is between 3.8 and 7.2%.

Zou et al. (2020) reported that non-respiratory symptoms may be explained by the binding of the virus to ACE-2 in other organs. Shen and Wang (2020) proved that ACE-2 is also expressed by testicular cells (namely spermatogonia, Leydig cells and Sertoli cells) which makes them potential targets for the virus. In fact, there are reports of orchitis and epididymitis in patients diagnosed with COVID-19. This means that SARS-CoV-2 may directly damage testicular tissue potentially compromising male fertility.

In a number of studies, PCR did not detect the virus in semen samples obtained during both the acute phase and recovery phase. In another study, postmortem needle and open biopsies of the testicles performed within an hour after death from COVID-19 revealed that testicular tissues were free of SARS-CoV-2 in 10 of 11 cases (91%). At the same time, spermograms in COVID-19 patients showed low ejaculate volume, sperm motility and sperm count. Previously, it was shown that COVID-19 has a severe effect on vasculature and therefore a microthrombi could be a possible contributor to fertility impairment. An assessment of testes with a Doppler enhanced ultrasound was therefore necessary.

Data dedicated to testosterone levels in the blood and inflammatory markers in the semen and testicular tissues is lacking. Available literature indicates changes in the above-mentioned parameters in males with verified COVID-19.

There is ultimately too little information to draw reliable conclusions regarding the effects of the virus on male reproduction. Published reports are limited by small study groups, lack of the control group and absence of follow-up examinations during recovery warranting further research and in-depth exploration of the topic.

Enrollment: 88 estimated patients

Sex: Male

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Clinical or imaging signs of COVID-19 infection
• Nasopharyngeal swab positive for SARS-CoV2 mRNA

Exclusion criteria

• Inability to collect semen for analysis
• Congenital anomalies of the testes
• Varicocele
• A history of fertility disorders

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

88 participants in 2 patient groups

Patients with COVID-19

Experimental group

Description:

Patients with confirmed COVID-19 infection

Treatment:

Diagnostic Test: hormone levels (testosterone, FSH, LH, prolactin)

Diagnostic Test: Sperm test

Other: Testis pathology samples

Diagnostic Test: SARS-CoV-2 Ig G levels

Healthy participants

Other group

Description:

The controlled group with healthy participants without COVID-19 infection.

Treatment:

Diagnostic Test: hormone levels (testosterone, FSH, LH, prolactin)

Diagnostic Test: Sperm test

Diagnostic Test: SARS-CoV-2 Ig G levels